[go: up one dir, main page]

ZA963281B - Alpha-substituted pyrimidine-thioalkyl and alkylether compounds. - Google Patents

Alpha-substituted pyrimidine-thioalkyl and alkylether compounds.

Info

Publication number
ZA963281B
ZA963281B ZA9603281A ZA963281A ZA963281B ZA 963281 B ZA963281 B ZA 963281B ZA 9603281 A ZA9603281 A ZA 9603281A ZA 963281 A ZA963281 A ZA 963281A ZA 963281 B ZA963281 B ZA 963281B
Authority
ZA
South Africa
Prior art keywords
thioalkyl
compounds
formula
alpha
substituted pyrimidine
Prior art date
Application number
ZA9603281A
Other languages
English (en)
Inventor
Richard A Nugent
Michael J Murphy
Richard C Thomas
Gary J Cleek
Stephen T Schlachter
Joel Morris
Donn G Wishka
David R Graber
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA963281B publication Critical patent/ZA963281B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ZA9603281A 1995-05-08 1996-04-24 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds. ZA963281B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08

Publications (1)

Publication Number Publication Date
ZA963281B true ZA963281B (en) 1997-10-24

Family

ID=23733510

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603281A ZA963281B (en) 1995-05-08 1996-04-24 Alpha-substituted pyrimidine-thioalkyl and alkylether compounds.

Country Status (26)

Country Link
US (1) US6043248A (fr)
EP (2) EP1449835A3 (fr)
JP (1) JPH11507017A (fr)
KR (1) KR100445498B1 (fr)
CN (2) CN1152022C (fr)
AT (1) ATE275550T1 (fr)
AU (1) AU712404B2 (fr)
BR (1) BR9608265A (fr)
CA (1) CA2216099C (fr)
CZ (1) CZ293135B6 (fr)
DE (1) DE69633332T2 (fr)
ES (1) ES2227586T3 (fr)
GE (1) GEP20002297B (fr)
HU (1) HUP9801995A3 (fr)
IL (1) IL118075A0 (fr)
MX (1) MX9708582A (fr)
NO (1) NO310287B1 (fr)
NZ (1) NZ307089A (fr)
PL (1) PL323240A1 (fr)
PT (1) PT824524E (fr)
RU (1) RU2167155C2 (fr)
SK (1) SK150297A3 (fr)
TW (1) TW450962B (fr)
UA (1) UA56992C2 (fr)
WO (1) WO1996035678A1 (fr)
ZA (1) ZA963281B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124306A (en) * 1997-09-25 2000-09-26 Pharmacia & Upjohn Company Thioalkyl alpha substituted pyrimidine compounds
US6111111A (en) 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
EP1121129B1 (fr) 1998-09-17 2008-09-03 Bristol-Myers Squibb Company Procede de traitement de diabetes a l'aide de l'inhibiteur ap2 et combinaison associee
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
EP1206260A4 (fr) 1999-06-30 2002-10-30 Merck & Co Inc Composes inhibiteurs de la src kinase
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
ES2755273T3 (es) * 2004-12-03 2020-04-22 Merck Sharp & Dohme Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación
CN101133038B (zh) * 2005-03-04 2012-06-27 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯基)-6-羟氨基嘧啶
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用
WO2011103559A1 (fr) 2010-02-22 2011-08-25 Nektar Therapeutics Composés diaromatiques substitués modifiés par un oligomère
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
TWI453208B (zh) * 2010-07-02 2014-09-21 Gilead Sciences Inc 治療性化合物類
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3324977B1 (fr) 2015-07-22 2022-07-13 Enanta Pharmaceuticals, Inc. Dérivés benzodiazépine utilisés comme inhibiteurs du virus respiratoire syncytial (rsv)
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
AU2020357452A1 (en) * 2019-10-04 2022-05-12 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
US20230112484A1 (en) * 2020-01-20 2023-04-13 Agrematch Ltd. Compositions for crop protection
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
US20250084071A1 (en) * 2022-01-12 2025-03-13 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
US3940240A (en) * 1974-07-11 1976-02-24 Ina Seito Co., Ltd. Baking method and kiln for tile
EP0124630B1 (fr) * 1983-05-05 1987-01-28 LUDWIG HEUMANN & CO GMBH Dérivés de pyrimidinothioalkyle pyridine, procédé pour leur préparation et médicaments contenant ces composés
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
WO1989011279A1 (fr) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Compose heteropolycyclique non fusionne ayant une interaction avec des acides nucleiques
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
EP0507861B1 (fr) * 1989-12-28 1996-09-11 The Upjohn Company Composes anti-sida diaromatiques substitues
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
WO1993001181A1 (fr) * 1991-07-03 1993-01-21 The Upjohn Company Indoles substitues utilises comme produits pharmaceutiques dans le traitement du sida
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
WO1995007901A1 (fr) * 1993-09-17 1995-03-23 The Upjohn Company Acides tetroniques substitues utiles dans le traitement du vih et d'autres retrovirus
WO1995013267A1 (fr) * 1993-11-12 1995-05-18 The Upjohn Company Composes a base de pyrimidine-thioalkyle et d'alkylether
AU2395095A (en) * 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
CN1157610A (zh) * 1994-07-20 1997-08-20 比克·古尔顿·劳姆贝尔格化学公司 抗螺杆菌的吡啶基硫基化合物

Also Published As

Publication number Publication date
CN1183773A (zh) 1998-06-03
NO310287B1 (no) 2001-06-18
KR19990008400A (ko) 1999-01-25
CN1535958A (zh) 2004-10-13
EP0824524A1 (fr) 1998-02-25
EP1449835A2 (fr) 2004-08-25
KR100445498B1 (ko) 2004-11-16
DE69633332T2 (de) 2005-09-22
CZ349197A3 (cs) 1998-04-15
HUP9801995A3 (en) 1999-04-28
RU2167155C2 (ru) 2001-05-20
US6043248A (en) 2000-03-28
NZ307089A (en) 1999-07-29
PT824524E (pt) 2005-01-31
NO975129L (no) 1998-01-07
WO1996035678A1 (fr) 1996-11-14
DE69633332D1 (de) 2004-10-14
AU712404B2 (en) 1999-11-04
CA2216099C (fr) 2005-09-13
JPH11507017A (ja) 1999-06-22
CA2216099A1 (fr) 1996-11-14
SK150297A3 (en) 1998-10-07
HUP9801995A2 (hu) 1999-03-29
PL323240A1 (en) 1998-03-16
IL118075A0 (en) 1996-08-04
ATE275550T1 (de) 2004-09-15
NO975129D0 (no) 1997-11-07
CN1152022C (zh) 2004-06-02
CZ293135B6 (cs) 2004-02-18
EP0824524B1 (fr) 2004-09-08
EP1449835A3 (fr) 2004-09-15
ES2227586T3 (es) 2005-04-01
MX9708582A (es) 1998-02-28
GEP20002297B (en) 2000-11-25
UA56992C2 (uk) 2003-06-16
AU5635396A (en) 1996-11-29
BR9608265A (pt) 1999-02-02
TW450962B (en) 2001-08-21
HK1009446A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
IL118075A0 (en) Alpha-substituted pyrimidine-thioalkyl and alkylether compounds
ATE250063T1 (de) Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
LV12719A (lv) Benzoxazinones as inhibitors of hiv reverse transcriptase
EP1349562A4 (fr) Inhibition du gs-fdh pour moduler la bioactivite du monoxyde d'azote
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
GR3029370T3 (en) Compounds and methods for inhibition of hiv and related viruses
DK0604183T3 (da) HIV-protease-inhibitorer anvendelige i behandlingen af AIDS
WO1999019304A3 (fr) Composes de pyrimidine thioalkyl alpha substitues
ATE304364T1 (de) Chromium/biotin behandlung von typ-ii diabetes
MX9708452A (es) Inhibidores de sialidasa bacteriana y metodos para fabricar y usar la misma.
DE69322250D1 (de) 3-hydroxypyridin-4-on-derivate als chelatbildner
ZA991029B (en) Composition and methods for treatment of hiv infections.
MXPA03001081A (es) Medicamento anti-inflamatorio.
RU95110887A (ru) Ингибирующие орнитин-декарбоксилазу циклические аминоокисления
TR200103704T2 (tr) Terapötik ajanlar
DE3780191D1 (de) Octahydroindolizine analgesica und 7-keto-zwischenprodukte.
SE9402241D0 (sv) Inhibitor
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
NO951608L (no) Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon
ATE113843T1 (de) Verwendung eines prolylendopeptidase-inhibitors zur behandlung von aids.
TW252043B (fr)
EP0653207A4 (fr) Composition inhibitrice d'une infection par le virus du sida.
DK0457336T3 (da) Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat
KR920000747A (ko) Hiv역전사효소의 억제제
CA2155129A1 (fr) Combinaisons d'inhibiteurs retroviraux